Anti-HIV False Positivity Rate in Pregnant Women; and Investigating the Factors Affecting This Situation
Sponsor
Kanuni Sultan Suleyman Training and Research Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT03777371
Collaborator
(none)
128
59
Study Details
Study Description
Brief Summary
HIV virus is an etiologic agent of ( AIDS ) immunodeficiency syndrome . It is known that the estimated rate of transfer from mother to baby is 25% to 45%, pregnancy rate is 5-10%, pregnancy rate is 15-20% and in lactation period is 5-10%. Risk factors; maternal viral load, breastfeeding, vaginal birth, and prematurity. Although there is a high rate of false positivity in prenatal screening in our country, one of the factors affecting this is the number of pregnancies.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Actual Enrollment
:
128 participants
Observational Model:
Other
Time Perspective:
Retrospective
Official Title:
Anti-HIV False Positivity Rate in Pregnant Women; and Investigating the Factors Affecting This Situation
Actual Study Start Date
:
Jan 1, 2014
Actual Primary Completion Date
:
Dec 1, 2018
Actual Study Completion Date
:
Dec 1, 2018
Outcome Measures
Primary Outcome Measures
- The effect of the number of pregnancies on Anti HIV false positivity rate [5 years]
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Anti HIV seropositive Pregnant Women
Exclusion Criteria:
- Anti HIV seronegative Pregnant Women
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Kanuni Sultan Suleyman Training and Research Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Pınar Yalcin bahat,
Principal Investigator,
Kanuni Sultan Suleyman Training and Research Hospital
ClinicalTrials.gov Identifier:
NCT03777371
Other Study ID Numbers:
- HIVinPregnancies
First Posted:
Dec 17, 2018
Last Update Posted:
Dec 17, 2018
Last Verified:
Dec 1, 2018
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: